Our Gilead stock price prediction shows gains ahead, even after Gilead Sciences Inc. (Nasdaq: GILD) shares have fallen more than 7% since the beginning of August.
You see, the Gilead stock price recently got caught up in a sell-off of biotech stocks as regulators continue to investigate companies for drug price gouging.
But the stock price's drop has only made GILD stock more attractive
Our Gilead stock price prediction shows gains ahead, even after Gilead Sciences Inc. (Nasdaq: GILD) shares have fallen more than 7% since the beginning of August.
You see, the Gilead stock price recently got caught up in a sell-off of biotech stocks as regulators continue to investigate companies for drug price gouging.
But the stock price's drop has only made GILD stock more attractive
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Sometimes Washington triggers a stock move that can hand us outsized gains. That's exactly what happened with Gilead Sciences Inc. (Nasdaq: GILD).
In March 2014, U.S. Rep. Henry Waxman (D-CA) lashed out at the cost of Gilead's newly approved Hepatitis C (HCV) drug, Sovaldi. Sovaldi runs $84,000, or $1,000 a pill.
But Waxman missed the obvious. Sovaldi (and its newer version Harvoni) cures 90% of HCV patients. That means patients can avoid the need for a liver transplant - an operation that runs $250,000 if an organ donor is found. And that price doesn't include antirejection drugs and antibiotics people must take for the rest of their lives.
Still, Gilead sold off on fears that its high cost would make Medicare look to another HCV drug maker with a less expensive solution. GILD stock lost 13% of its value in a matter of days.
Wall Street was dead wrong...
Medicare actually spent $4.6 billion on Hepatitis C treatments in the first six months of this year. That's almost as much as the agency spent in all of 2014. Gilead accounted for 66% of all covered prescriptions.
And since April 2014, Gilead has gained 66.5% - more than four times that of the S&P 500.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
While others get distracted by the noise on Wall Street, we're staying focused on our long-term objective of building wealth through tech investing.
No one else in the mainstream media is covering the fact that tech is still performing better than the overall market and will continue to outperform.
And these three tech stocks will lead the pack...
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Today we're taking a look at four of your most perceptive investing questions. We also answer an inquiry from Stuart Varney.
After all, we know it's far more profitable to learn from each other than it is to go down the road alone. Chances if you're thinking about something, another investor is, too.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill.
According to The Wall Street Journal, many states have restricted access to the drug, leaving some patients unable to afford the treatment.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Dividend Investing News, Feb. 9, 2015: Stocks that sport attractive and growing dividends are still the best option for income seekers as interest rates remain low.
More than half of S&P 500 companies currently yield more than the 10-year Treasury note's 1.93%. Plus, dividend stocks offer an added bonus of potential capital appreciation.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Our 2015 stock picks show us two trends.
Precious metals are still surging. And now, biotech stocks are coming into 2015 hot.
Take a look at these exciting developments for our top stocks in 2015...
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Today I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.
This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
In technical analysis, you study a stock's chart to figure out if it's about to soar, ready to plummet, or just treading water.
And in my 30 years knocking around Silicon Valley, I've found that the stocks with the best charts tend to be small caps.
But not all stocks with eye-popping charts are risky small caps.
My charts have revealed two big-cap tech stocks with small-cap charts.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.
Here are a closer look at the priciest drugs – and the biotech stocks behind them…
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.
Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.
Start the conversation
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, the stock was up 3% from yesterday's closing price.
Money Morning’s Defense and Tech Specialist Michael Robinson has been high on GILD stock for some time, and yesterday’s huge earnings beat comes as no surprise to Money Morning readers.
Here’s why this hot biotech stock is just getting started.
Start the conversation